Skip to content
Menu

Guggenheim Initiates Coverage On Corbus Pharmaceuticals with Buy Rating, Announces Price Target of $45

Benzinga Newsdesk 6 months ago

NewsPrice TargetInitiationAnalyst Ratings

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and announces Price Target of $45.

Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and announces Price Target of $45.

Read at benzinga.com